Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Partnership to China Amid High Cancer Burden
核心洞察
Pillar Biosciences (搜索) and AstraZeneca have expanded their laboratory access program for NGS-based liquid biopsy tumor profiling to include China, aiming to deliver rapid and cost-effective genomic insights.
The partnership addresses China's significant cancer burden, which accounts for approximately 24% of new global cancer cases and 30% of cancer-related deaths according to WHO's GLOBOCAN 2022 report.
The collaboration involves Shanghai Zhengu Biological Technology Co. (搜索) to support assay validation in local hospital laboratories and implement Pillar's liquid biopsy panels for localized tumor profiling.
Pillar Biosciences (搜索) and AstraZeneca have announced a significant expansion of their existing laboratory access program for next-generation sequencing (NGS)-based liquid biopsy tumor profiling to include China, addressing one of the world's most pressing cancer healthcare challenges.
The expanded collaboration aims to deliver rapid, cost-effective, and clinically actionable genomic insights through liquid biopsy testing. By increasing the local availability of plasma-based tumor profiling at leading clinical laboratories in China, the partnership seeks to accelerate diagnostic turnaround times and improve access to precision oncology solutions.
Addressing China's Cancer Crisis
China faces one of the world's highest cancer burdens, accounting for approximately 24% of new global cancer cases and 30% of cancer-related deaths, according to the World Health Organization's GLOBOCAN 2022 report. Lung, colorectal, and liver cancers remain among the most prevalent, and access to early detection and molecular diagnostics continues to be a significant healthcare challenge.
By expanding localized liquid biopsy testing, this collaboration supports China's ongoing initiatives to enhance early cancer detection, precision diagnostics, and equitable access to targeted therapies.
Strategic Implementation Framework
As part of the initiative, AstraZeneca, Pillar Biosciences (搜索), and Shanghai Zhengu Biological Technology Co. (搜索), Ltd. (Zhengu) will collaborate to support assay validation in local hospital laboratories and facilitate the implementation of Pillar's liquid biopsy panels to enable localized tumor profiling.
"Expanding access to decentralized, high-quality molecular testing is critical to improving outcomes for cancer patients," said Dan Harma, Chief Commercial Officer, Pillar Biosciences (搜索). "By enabling local laboratories to perform in-house next-generation sequencing, we can reduce turnaround times, lower costs, and ensure that oncologists have faster access to actionable insights that guide personalized treatment decisions."
Technology Platform and Capabilities
Pillar Biosciences (搜索) leverages its proprietary SLIMamp® and PiVAT® technologies to optimize precision therapy selection for cancer patients, from tumor profiling to treatment selection and recurrence monitoring. The company's localized testing approach helps reduce diagnostic costs, improve turnaround times, and expand access to high-quality NGS testing globally.
The company offers more than 20 NGS testing kits in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences (搜索) is headquartered in Natick, Massachusetts, and positions itself as a leader in Decision Medicine™.